Abstract Submission for Invited Speakers
Please refer to the following guidelines and submit your abstracts by accessing the submission system by clicking the "Abstract Submission" button located at the bottom of this page.
- Abstract Submission Guidelines
- Publication in “Annals of Oncology”
- Disclosure of Conflict of Interest at 2024 the Japanese Society of Medical Oncology Annual Meeting
- Ethical Principles for Declaring Ethical Matters of your Abstract
- Abstract Submission
- Confirmation / Modification / Deletion of Submitted Abstract Page
- Inquiries for Abstract Submission
Abstract Submission Guidelines
- Author information and abstracts must be submitted in English.
- Abstract title is limited to 150 single-byte characters. (including spaces)
- Abstract is limited to 2,000 single-byte characters. (including spaces)
- A maximum of 20 authors (first author & co-authors) may be registered.
- A maximum of 20 affiliations (including the affiliation of the first author) may be registered.
- Any chart or diagram cannot be included.
- In the registration page, you will be asked to enter the information such as "application for "about in Encore Abstract", "publication in Annals of Oncology" as well as COI information.
- It is recommended that you prepare your abstract text by Word/ text file in advance, and then copy it on the registration page.
- After completing the abstract submission, the abstract registration ID number and your password will be sent to the first author’s email address. The ID number and password will be required to confirm/modify/delete abstracts. Please be sure to enter the correct e-mail address. Please be sure to keep the ID number and password by yourself. The congress secretariat will NOT keep track of your information.
Publication in “Annals of Oncology”
Abstracts submitted in English for JSMO2024 will be published in ESMO/JSMO Scientific Journal, supplement to "Annals of Oncology" (Elsevier).
If you wish to have your abstract published in "Annals of Oncology," please select "Yes".
However, in case that there is any possibility of duplicate publication or encore publication, please refrain from selecting "Yes".
Disclosure of Conflict of Interest at 2024 the Japanese Society of Medical Oncology Annual Meeting
The presenter (the first author) and the principal investigator must disclose the name of any company or for-profit organization related to medicine they have a relationship with, defined as follows: in the following items (3) to (9), (11), (12), exceeding separately stipulated criteria, and (1), (2), (10), (13) if met. The subject period is from January 1, 2020 - December 31, 2022.
To view the PDF files, you may need, "Adobe Reader" (Download Adobe Reader）
COI Policy (in revision)
Detailed Enforcement Regulations of COI (in revision)
For oral presentation, please use the slide below as a template to disclose conflict of interest.
For poster presentation, please prepare and print out the slide, and put it at lower right of the poster panel.
↓ Swipe sideways to see.
| 1 | If your study for this presentation is supported by research funds |
|---|---|
| 2 | If you are or have been an employee of a company and / or a profit-making organization related to medicine |
| 3 | If you have earned > ¥1,000,000 / year as an officer or advisor of a company and/or a profit-making organization related to medicine |
| 4 | If you hold > 5% of the stock of a company and/or a profit-making organization related to medicine, or receive dividends >¥1,000,000/year |
| 5 | If you have earned > ¥1,000,000/year as a patent fee from a company and / or a profit-making organization related to medicine |
| 6 | If you have earned > ¥500,000/year as a lecture fee from a company and / or a profit-making organization related to medicine |
| 7 | If you have earned > ¥500,000/year as a manuscript fee from a company and / or a profit-making organization related to medicine |
| 8 | If you have received > ¥1,000,000/year as research expenses from a company and / or a profit-making organization related to medicine |
| 9 | If you have received > ¥1,000,000/year as a certain contribution from a company and / or a profit-making organization related to medicine |
| 10 | If you are or have been involved in a certain endowed chair funded by a company and / or a profit-making organization related to medicine |
| 11 | If you have earned > ¥1,000,000/year as a fee for expert comment, judgment or testimony in legal proceedings, or others froma company and / or a profit-making organization related to medicine |
| 12 | If you have received remuneration (travel, gifts, or other in-kind payments not directly related to research) equivalent to >¥50,000/year from a company and / or a profit-making organization related to medicine |
| 13 | If you are a representative of an organization for clinical study which receives research expenses (donation, contract, others)from a company and/or a profit-making organization related to medicine |
Inquiries regarding COI disclosure
- The Secretariat of the Japanese Society of Medical Oncology
- E-mail: support@jsmo.or.jp
Ethical Principles for Declaring Ethical Matters of your Abstract
In order to review whether your abstract is conformed to the standard of applicable research ethics such as "GCP", "GPSP", "Ethical guidelines on medical research on humans", "Ethical guidelines on research on human genome and gene analysis", etc., JSMO asks you to declare the following items: The content of your declaration will not affect the acceptance or rejection of your abstract. Please submit to the following:
- Does your study include medical research on human subjects, human material or human data?
- Required
- Does your study comply with the Declaration of Helsinki?
- Was your study approved by an institutional review board before starting the research?
Abstract Submission
Confirmation / Modification / Deletion of Submitted Abstract Page
Inquiries for Abstract Submission
- Congress Secretariat
- c/o Congrès Inc.
- Onward Park Bldg., 3-10-5 Nihonbashi, Chuo-ku Tokyo 103-8276, JAPAN
- E-mail：jsmo2024-abs@congre.co.jp